Description of Abeona Therapeutics Inc's Business Segments
Abeona Therapeutics Inc. is a biotechnology company that focuses on the development of gene and cell therapies for the treatment of rare and serious genetic diseases. The company is committed to transforming the lives of patients through innovative therapies that address significant unmet medical needs. Below, I provide a detailed overview of the segments, products, and services offered by Abeona Therapeutics.
Segments
1. Gene Therapy: - Abeonas gene therapy segment deals with the application of genetic material to treat or prevent diseases. The companys approach often involves introducing corrected copies of defective genes into the patient’s cells. This segment is particularly focused on diseases that currently have limited treatment options.
2. Cell Therapy: - The cell therapy segment encompasses treatments that involve the infusion of healthy cells into a patient to treat diseases. This can include various types of stem cell therapies that aim to restore normal function to affected tissues.
3. Rare Diseases: - A key focus area for Abeona is the development of therapies for rare diseases, particularly those that stem from genetic mutations. The company aims to create targeted therapies that address the root cause of these diseases, offering hope for patients with limited alternatives.
Products
1. AAV-CSPG4: - This is an investigational gene therapy designed for the treatment of certain cancers and neurological diseases. It utilizes adeno-associated virus (AAV) technology to deliver a gene payload that targets CSPG4, a protein associated with tumor development.
2. EB-101: - EB-101 is an investigational cell therapy specifically designed for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disorder. The product involves the use of genetically modified skin cells to restore production of the collagen type that is deficient in affected patients.
3. AB-201: - This is another investigational gene therapy targeting Sanfilippo Syndrome, a rare genetic disorder that affects the bodys ability to break down certain sugars. The therapy aims to deliver a functional copy of the gene that is malfunctioning in patients with Sanfilippo Syndrome.
Services
1. Clinical Development Services: - Abeona offers comprehensive clinical development services to advance its therapies through various phases of clinical trials. This includes preclinical research, clinical study design, regulatory strategy, and patient recruitment efforts.
2. Manufacturing Capabilities: - The company has developed robust manufacturing capabilities to produce its gene and cell therapies according to Good Manufacturing Practices (GMP). This includes scalable production methods that ensure the purity, potency, and quality of the therapeutic products.
3. Regulatory Affairs: - Abeona has a dedicated team that navigates the complex regulatory landscape of gene and cell therapy products. This service includes preparing and submitting documentation to regulatory agencies, ensuring compliance with all guidelines, and obtaining necessary approvals for clinical trials and product commercialization.
4. Collaboration and Partnerships: - Abeona actively seeks collaborations with other biotechnology firms, academic institutions, and research organizations. These partnerships are aimed at leveraging additional expertise and resources to accelerate the development of its therapies and enhance the overall impact of its R&D efforts.
Conclusion
Abeona Therapeutics Inc. is a pioneering company focused on addressing the challenges of rare and complex genetic diseases through advanced gene and cell therapies. With dedicated segments targeting both gene and cell innovations, the company is poised to make significant contributions to the fields of biotechnology and therapeutics, improving the quality of life for individuals suffering from these debilitating conditions. The comprehensive suite of services complements its product offerings, enabling the company to bring its innovative treatments to market effectively.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
86.56 %